The Association Between Reproductive and Hormonal Factors and Ovarian Cancer by Estrogen-α and Progesterone Receptor Status

Overview

Journal Gynecol Oncol

Date 2016 Oct 11

PMID 27720231

Citations 19

Authors

Amy L Shafrir

Megan S Rice

Mamta Gupta

Kathryn L Terry

Bernard A Rosner

Rulla M Tamimi

Jonathan L Hecht

Shelley S Tworoger

Affiliations

Soon will be listed here.

Abstract

Objective: We assessed the association between reproductive and hormonal factors and ovarian cancer incidence characterized by estrogen receptor-α (ERα) and progesterone receptor (PR) status.

Methods: Tissue microarrays were used to assess ERα and PR expression among 197 Nurses' Health Study (NHS), 42 NHSII and 76 New England Case-Control Study (NECC) ovarian cancer cases. NHS/NHSII cases were matched to up to 4 controls (n=954) on diagnosis date and birth year. NECC controls (n=725) were frequency matched on age. Cases were considered receptor positive if ≥1% of tumor cells stained positive. Associations by ERα and PR status were assessed using polytomous logistic regression. p-Value for heterogeneity was calculated using a likelihood ratio test.

Results: 45% of ovarian tumors were PR(+), 78% were ERα(+) and 45% were ERα(+)/PR(+), while 22% were ERα(-)/PR(-). Postmenopausal status was associated with an increased risk of PR(-) tumors (OR: 2.07; 95%CI: 1.15-3.75; p-heterogeneity=0.01) and age at natural menopause was inversely associated with PR(-) tumors (OR, per 5years: 0.77; 95%CI: 0.61-0.96; p-het=0.01). Increasing duration of postmenopause was differentially associated by PR status (p-het=0.0009). Number of children and tubal ligation were more strongly associated with ERα(-) versus ERα(+) tumors (p-het=0.002 and 0.05, respectively). No differential associations were observed for oral contraceptive or hormone therapy use.

Conclusions: Postmenopausal women have an increased risk of developing PR(-) ovarian tumors compared to premenopausal women. The associations observed for ovarian cancer differ from those seen for breast cancer suggesting that the biology for tumor development through ERα and PR pathways may differ.

Citing Articles

Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival-A prospective cohort study in Australia.

Na R, Jordan S, DeFazio A, Williams M, Livingstone K, Obermair A Int J Cancer. 2024; 156(2):280-292.

PMID: 39222307 PMC: 11578076. DOI: 10.1002/ijc.35154.

How Progesterone Receptor Expression Impacts Platinum Sensitivity in Ovarian Clear Cell Carcinoma: Insights from Clinical and Experimental Perspectives.

Wu C, Fu H, Ou Y, Chuang I, Lan J, Yang M Int J Mol Sci. 2024; 25(14).

PMID: 39063185 PMC: 11276830. DOI: 10.3390/ijms25147942.

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer.

Skold C, Corvigno S, Dahlstrand H, Enblad G, Mezheyeuski A, Sundstrom-Poromaa I Cancer Causes Control. 2024; 35(8):1101-1109.

PMID: 38578428 PMC: 11266373. DOI: 10.1007/s10552-024-01876-2.

17β-hydroxysteroid dehydrogenase type 1 improves survival in serous epithelial ovarian tumors.

Pedernera E, Morales-Vasquez F, Gomora M, Almaraz M, Mena E, Perez-Montiel D Endocr Connect. 2023; 12(12).

PMID: 37924640 PMC: 10762561. DOI: 10.1530/EC-23-0315.

Estrogens and the risk of breast cancer: A narrative review of literature.

Al-Shami K, Awadi S, Khamees A, Alsheikh A, Al-Sharif S, Ala Bereshy R Heliyon. 2023; 9(9):e20224.

PMID: 37809638 PMC: 10559995. DOI: 10.1016/j.heliyon.2023.e20224.

References

Cibula D, Widschwendter M, Zikan M, Dusek L . Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand. 2011; 90(6):559-63. DOI: 10.1111/j.1600-0412.2011.01114.x. View

Glynn R, Rosner B . Methods to evaluate risks for composite end points and their individual components. J Clin Epidemiol. 2004; 57(2):113-22. DOI: 10.1016/j.jclinepi.2003.02.001. View

Tung K, Goodman M, Wu A, McDuffie K, Wilkens L, Kolonel L . Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol. 2003; 158(7):629-38. DOI: 10.1093/aje/kwg177. View

Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R . Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res. 1990; 50(21):7057-61. View

Vang R, Whitaker B, Farhood A, Silva E, Ro J, Deavers M . Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol. 2001; 20(3):252-9. DOI: 10.1097/00004347-200107000-00008. View

Sieh W, Salvador S, McGuire V, Weber R, Terry K, Rossing M . Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol. 2013; 42(2):579-89. PMC: 3619957. DOI: 10.1093/ije/dyt042. View

Terry K, De Vivo I, Titus-Ernstoff L, Sluss P, Cramer D . Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol. 2005; 161(5):442-51. PMC: 1380205. DOI: 10.1093/aje/kwi064. View

Kurman R, Shih I . Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008; 27(2):151-60. PMC: 2794425. DOI: 10.1097/PGP.0b013e318161e4f5. View

Nardulli A, Greene G, OMalley B, Katzenellenbogen B . Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology. 1988; 122(3):935-44. DOI: 10.1210/endo-122-3-935. View

10.

Mukherjee K, Syed V, Ho S . Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene. 2005; 24(27):4388-400. DOI: 10.1038/sj.onc.1208623. View

11.

Shih I, Kurman R . Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5):1511-8. PMC: 1615664. DOI: 10.1016/s0002-9440(10)63708-x. View

12.

Ma H, Bernstein L, Pike M, Ursin G . Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006; 8(4):R43. PMC: 1779465. DOI: 10.1186/bcr1525. View

13.

Jun H, Austin S, Wylie S, Corliss H, Jackson B, Spiegelman D . The mediating effect of childhood abuse in sexual orientation disparities in tobacco and alcohol use during adolescence: results from the Nurses' Health Study II. Cancer Causes Control. 2010; 21(11):1817-28. PMC: 2962696. DOI: 10.1007/s10552-010-9609-3. View

14.

Huang W, Newman B, Millikan R, Schell M, Hulka B, Moorman P . Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2001; 151(7):703-14. DOI: 10.1093/oxfordjournals.aje.a010265. View

15.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

16.

Karst A, Drapkin R . Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2009; 2010:932371. PMC: 2739011. DOI: 10.1155/2010/932371. View

17.

Harding M, Cowan S, Hole D, Cassidy L, Kitchener H, Davis J . Estrogen and progesterone receptors in ovarian cancer. Cancer. 1990; 65(3):486-91. DOI: 10.1002/1097-0142(19900201)65:3<486::aid-cncr2820650319>3.0.co;2-c. View

18.

Stampfer M, Willett W, Speizer F, Dysert D, Lipnick R, Rosner B . Test of the National Death Index. Am J Epidemiol. 1984; 119(5):837-9. DOI: 10.1093/oxfordjournals.aje.a113804. View

19.

Gates M, Rosner B, Hecht J, Tworoger S . Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2009; 171(1):45-53. PMC: 2796984. DOI: 10.1093/aje/kwp314. View

20.

Sylvia M, Kumar S, Dasari P . The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Indian J Pathol Microbiol. 2012; 55(1):33-7. DOI: 10.4103/0377-4929.94852. View